The history of botulinum toxin type A extends far beyond its well-known cosmetic applications. According to a review in PubMed Central on the clinical history of botulinum toxins, ophthalmologist Alan Scott pioneered its therapeutic use for strabismus, conducting early clinical work before broader adoption in the 1980s. By the mid-1980s, thousands of patients had participated in large clinical trials, establishing botulinum toxin as a treatment for eye-muscle disorders. At that stage, its use was strictly medical.
The 1987 Observation in Blepharospasm Treatment
A significant breakthrough occurred in 1992 during treatment. As noted in a peer-reviewed review published on PubMed Central, Jean and Alastair Carruthers observed a visible reduction of furrows between the eyebrows (glabellar area) in patients receiving injections of botulinum toxin type A, along with improved skin appearance near the eye. These observations were beyond the initial treatment goal and were made incidentally during therapy, yet they became consistent across patients. The same review highlights that this moment is widely regarded as a key early link between therapeutic botulinum toxin use and cosmetic improvement.
From Observation to Controlled Studies
Following that observation, more formal research began soon after. The Carruthers are believed to be among the first to embark on clinical research into the application of botulinum toxin for cosmetic wrinkle treatment. The first peer-reviewed reports on the aesthetic application of botulinum toxin type A appeared in 1988, marking its introduction into cosmetic medicine.
Anatomy Behind Wrinkle Changes
The cosmetic effect observed in eye clinics correlates with facial anatomy. According to a clinical review, glabellar frown lines are primarily produced by the action of the corrugator supercilii and procerus muscles through frequent contraction. When these muscles are relaxed, the overlying skin becomes smoother. This association explains why ophthalmic patients injected near these muscles experienced cosmetic effects. Another point from the review notes that muscle relaxation can also soften wrinkles when the face is animated.
From Therapeutic Use to Cosmetic Medicine
This transition occurred gradually and was controlled. As per one PubMed review, botulinum toxin type A was first approved in 1989 for ophthalmic conditions such as strabismus and blepharospasm. Its cosmetic approval for glabellar lines came much later, in 2002. Another comprehensive review substantiates this timeline, where medical application preceded cosmetic use by a decade through sustained research. One review describes this timeline as stepwise, starting with its use as an ophthalmological medication and then moving to accidental cosmetic usage alongside research.
Why the 1987 Moment Mattered
The significance of the 1987 discovery lies not in its being remarkable, but in its reproducibility in the clinic. It occurred in the area of the face associated with the treated muscles, making it possible to see and quantify the effects. As shown in clinical research literature, the coincidence of the treated area and the wrinkle area was the determining factor in recognizing the cosmetic effect in the early days; otherwise, it might have gone unrecognized. The cosmetic use of botulinum toxin emerged from ophthalmology practice rather than aesthetic research. The story began in the ophthalmologist's office, where physicians noted an unusual facial appearance in patients with eye-muscle disorders in 1987. As several clinical articles documented, these observations were followed by research and publications in the late 1980s, culminating in eventual FDA approval for cosmetic use in 2002. The transition from therapy to aesthetics was not immediate.
